CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives
Open Access
Abstract
Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease arising from loss-of-function mutations in the dystrophin gene and characterized by progressive muscle degeneration, respiratory insufficiency, cardiac failure, and premature death by the age of thirty. Albeit DMD is one of the most common types of fatal genetic diseases, there is no curative treatment for this devastating disorder. In recent years, gene editing via the clustered regularly interspaced short palindromic repeats (CRISPR) system has paved a new path toward correcting pathological mutations at the genetic source, thus enabling the permanent restoration of dystrophin expression and function throughout the musculature. To date, the therapeutic benefits of CRISPR genome-editing systems have been successfully demonstrated in human cells, rodents, canines, and piglets with diverse DMD mutations. Nevertheless, there remain some nonignorable challenges to be solved before the clinical application of CRISPR-based gene therapy. Herein, we provide an overview of therapeutic CRISPR genome-editing systems, summarize recent advancements in their applications in DMD contexts, and discuss several potential obstacles lying ahead of clinical translation.Keywords
Funding Information
- National Natural Science Foundation of China (82273475, 22ZR1449100, XDB32060000, 31871502, 31925016, 91957122, 82021001)
- Natural Science Foundation of Shanghai Municipality (82273475, 22ZR1449100, XDB32060000, 31871502, 31925016, 91957122, 82021001)
- Strategic Priority Research Program of the Chinese Academy of Science (82273475, 22ZR1449100, XDB32060000, 31871502, 31925016, 91957122, 82021001)
- National Natural Science Foundation of China (82273475, 22ZR1449100, XDB32060000, 31871502, 31925016, 91957122, 82021001)
This publication has 229 references indexed in Scilit:
- Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator systemCell Research, 2013
- Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidisProceedings of the National Academy of Sciences, 2013
- Autophagy as a new therapeutic target in Duchenne muscular dystrophyCell Death & Disease, 2012
- A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial ImmunityScience, 2012
- Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV VectorMolecular Therapy, 2012
- An intronic LINE-1 element insertion in the dystrophin gene aborts dystrophin expression and results in Duchenne-like muscular dystrophy in the corgi breedLaboratory Investigation, 2010
- Widespread Muscle Expression of an AAV9 Human Mini-dystrophin Vector After Intravenous Injection in Neonatal Dystrophin-deficient DogsMolecular Therapy, 2010
- Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin geneGene Therapy, 2010
- Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesisNature Reviews Molecular Cell Biology, 2010
- Effect of Genome Size on AAV Vector PackagingMolecular Therapy, 2010